Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | APOL1 | O14791 | 5/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006361 | 1.00 | PPARG (0.48) | PPARGAPOL1FBP1EGFRGPR17 | |
| SCHEMBL18509893 | 0.82 | EGFR (0.51) | FBP1EGFRKDM4EALDH1A1SRC | |
| SCHEMBL22118406 | 0.81 | APOL1 (0.62) | PPARGAPOL1FBP1EGFRGPR17 | |
| SCHEMBL22118399 | 0.81 | PPARG (0.51) | PPARGAPOL1FBP1EGFRGPR17 | |
| SCHEMBL22161270 | 0.78 | APOL1 (0.42) | APOL1 | |
| SCHEMBL31006380 | 0.78 | APOL1 (0.77) | APOL1 | |
| SCHEMBL22118374 | 0.78 | APOL1 (0.77) | APOL1 | |
| SCHEMBL31006381 | 0.78 | APOL1 (0.77) | APOL1 | |
| SCHEMBL6624875 | 0.77 | KDM4E (0.68) | PPARGEGFRKDM4EALDH1A1SRC | |
| SCHEMBL22118496 | 0.77 | APOL1 (0.62) | PPARGAPOL1FBP1EGFRGPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-02-06 | — | — | US | disclosed |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| CN-113453760-B | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3897833-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453760-A | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | PPARG 2729/4885APOL1 1/4885FBP1 541/4885 |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, SAAL1 | PPARG 2729/4885APOL1 1/4885FBP1 541/4885 |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | PPARG 2729/4885APOL1 1/4885FBP1 541/4885 |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | PPARG 1058/4885APOL1 1/4885FBP1 1049/4885 |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, SAAL1, LOXL1 | PPARG 2332/4885APOL1 1/4885FBP1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.